Outlook Therapeutics, Inc
Price
FilingsNewest: 8-K, Listing noticeSep 30 →Insiders6 insiders bought $5.3M in 6 open-market buys. No sales.→HoldersVanguard 2.3%Perceptive 1.7%Marshall Wace, LLP 1.1%→Financing →PeersClosest companies: ALMS, SYRE, VRDN→
From the filings
Figures
- Revenue
- $1.4Mlast 12 months
- Net income
- −$61.1Mlast 12 months
- Operating cash flow
- −$47.0Mlast 12 months
- Cash and equivalents
- $11.2Mat the last balance sheet
- Shares outstanding
- 187.1M shareson issue